| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 13 | 2023 | 481 | 4.820 |
Why?
|
| Bile Duct Neoplasms | 11 | 2024 | 493 | 4.390 |
Why?
|
| Cholangiocarcinoma | 11 | 2024 | 493 | 4.330 |
Why?
|
| Laparoscopy | 11 | 2023 | 1225 | 3.440 |
Why?
|
| Liver Neoplasms | 24 | 2023 | 4557 | 2.800 |
Why?
|
| Pancreatic Neoplasms | 28 | 2022 | 5061 | 2.100 |
Why?
|
| Colorectal Neoplasms | 15 | 2023 | 3578 | 1.650 |
Why?
|
| Hepatectomy | 19 | 2023 | 1011 | 1.610 |
Why?
|
| Pancreatectomy | 11 | 2021 | 652 | 1.540 |
Why?
|
| Robotics | 4 | 2022 | 359 | 1.520 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2023 | 167 | 1.510 |
Why?
|
| Bile Ducts, Intrahepatic | 8 | 2023 | 334 | 1.500 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2023 | 2027 | 1.310 |
Why?
|
| Gallbladder Neoplasms | 3 | 2023 | 245 | 1.270 |
Why?
|
| Neoadjuvant Therapy | 17 | 2023 | 4975 | 1.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2010 | 694 | 0.980 |
Why?
|
| Neoplasm Staging | 15 | 2022 | 13658 | 0.940 |
Why?
|
| Insurance | 1 | 2023 | 15 | 0.900 |
Why?
|
| Adenocarcinoma | 12 | 2022 | 7789 | 0.870 |
Why?
|
| Fluorescent Dyes | 5 | 2022 | 459 | 0.860 |
Why?
|
| Hospitals | 3 | 2020 | 485 | 0.830 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2023 | 42 | 0.820 |
Why?
|
| Cholecystectomy | 2 | 2021 | 107 | 0.820 |
Why?
|
| Chemoradiotherapy, Adjuvant | 5 | 2019 | 565 | 0.770 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 68 | 0.770 |
Why?
|
| Fluorescence | 7 | 2021 | 195 | 0.750 |
Why?
|
| Portal Vein | 4 | 2021 | 355 | 0.750 |
Why?
|
| Retrospective Studies | 42 | 2024 | 37905 | 0.750 |
Why?
|
| Humans | 104 | 2024 | 261506 | 0.740 |
Why?
|
| Postoperative Complications | 8 | 2023 | 5542 | 0.720 |
Why?
|
| Klatskin Tumor | 1 | 2020 | 29 | 0.720 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2019 | 3890 | 0.710 |
Why?
|
| Pancreaticoduodenectomy | 10 | 2023 | 690 | 0.700 |
Why?
|
| Lymph Node Excision | 4 | 2022 | 1959 | 0.700 |
Why?
|
| Carcinoma | 4 | 2012 | 2578 | 0.690 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 169 | 0.690 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 250 | 0.670 |
Why?
|
| Embolization, Therapeutic | 2 | 2021 | 551 | 0.650 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2022 | 255 | 0.650 |
Why?
|
| Diagnostic Imaging | 6 | 2016 | 1162 | 0.640 |
Why?
|
| Malnutrition | 2 | 2020 | 218 | 0.640 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 600 | 0.630 |
Why?
|
| Hernia, Abdominal | 1 | 2018 | 41 | 0.630 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2022 | 1724 | 0.620 |
Why?
|
| Immunoconjugates | 1 | 2021 | 279 | 0.610 |
Why?
|
| Patient Care Planning | 1 | 2019 | 297 | 0.580 |
Why?
|
| Lymph Nodes | 6 | 2023 | 2967 | 0.570 |
Why?
|
| Rectal Neoplasms | 5 | 2023 | 1202 | 0.550 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2012 | 222 | 0.510 |
Why?
|
| Preoperative Care | 2 | 2020 | 1529 | 0.510 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 107 | 0.500 |
Why?
|
| Mesenteric Veins | 2 | 2020 | 73 | 0.500 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2019 | 2231 | 0.490 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.480 |
Why?
|
| Liver | 3 | 2022 | 2961 | 0.480 |
Why?
|
| Treatment Outcome | 23 | 2023 | 32848 | 0.470 |
Why?
|
| Liver Diseases | 1 | 2019 | 574 | 0.470 |
Why?
|
| Mice, Nude | 13 | 2022 | 4307 | 0.460 |
Why?
|
| Pancreatic Diseases | 1 | 2014 | 108 | 0.450 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 1062 | 0.450 |
Why?
|
| Thyroid Neoplasms | 3 | 2016 | 1866 | 0.430 |
Why?
|
| Microscopy, Fluorescence | 3 | 2010 | 769 | 0.430 |
Why?
|
| Lymphatic System | 1 | 2011 | 64 | 0.400 |
Why?
|
| Drainage | 3 | 2018 | 416 | 0.390 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 4844 | 0.380 |
Why?
|
| Skin, Artificial | 1 | 2010 | 25 | 0.380 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2023 | 500 | 0.380 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2010 | 209 | 0.360 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 1371 | 0.360 |
Why?
|
| Thyroid Gland | 1 | 2012 | 355 | 0.360 |
Why?
|
| Female | 43 | 2023 | 141928 | 0.350 |
Why?
|
| Aged | 27 | 2023 | 70117 | 0.350 |
Why?
|
| Pancreas, Exocrine | 1 | 2009 | 22 | 0.340 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 750 | 0.340 |
Why?
|
| Middle Aged | 29 | 2023 | 86204 | 0.340 |
Why?
|
| Survival Rate | 12 | 2023 | 12221 | 0.330 |
Why?
|
| Cohort Studies | 9 | 2022 | 9244 | 0.330 |
Why?
|
| SEER Program | 1 | 2012 | 1000 | 0.330 |
Why?
|
| Colonic Neoplasms | 4 | 2022 | 1390 | 0.310 |
Why?
|
| Stomach Neoplasms | 4 | 2022 | 2278 | 0.310 |
Why?
|
| Gastrectomy | 5 | 2023 | 451 | 0.300 |
Why?
|
| Collagen | 1 | 2010 | 752 | 0.300 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 584 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 7702 | 0.290 |
Why?
|
| Male | 33 | 2023 | 123000 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 15862 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 7551 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2022 | 1303 | 0.270 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8865 | 0.260 |
Why?
|
| Neoplasms | 7 | 2024 | 15193 | 0.250 |
Why?
|
| United States | 10 | 2023 | 15433 | 0.250 |
Why?
|
| Cell Line, Tumor | 10 | 2022 | 14551 | 0.250 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 2927 | 0.250 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 7222 | 0.250 |
Why?
|
| Mammography | 1 | 2010 | 1010 | 0.250 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 4988 | 0.240 |
Why?
|
| Length of Stay | 3 | 2022 | 1900 | 0.240 |
Why?
|
| Anus Neoplasms | 2 | 2018 | 411 | 0.240 |
Why?
|
| Cholangitis | 1 | 2024 | 48 | 0.240 |
Why?
|
| Incisional Hernia | 1 | 2023 | 9 | 0.230 |
Why?
|
| Bayes Theorem | 3 | 2022 | 1021 | 0.230 |
Why?
|
| Nutritional Status | 3 | 2020 | 337 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 4367 | 0.220 |
Why?
|
| Receptors, Somatostatin | 2 | 2022 | 85 | 0.220 |
Why?
|
| Mammaplasty | 1 | 2010 | 780 | 0.220 |
Why?
|
| Hypertension, Portal | 1 | 2024 | 124 | 0.220 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 15694 | 0.220 |
Why?
|
| Teaching Rounds | 1 | 2022 | 33 | 0.220 |
Why?
|
| Neoplasm Metastasis | 4 | 2013 | 5112 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2010 | 3821 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6207 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Pancreatitis, Chronic | 1 | 2022 | 116 | 0.210 |
Why?
|
| Mice | 15 | 2022 | 34495 | 0.210 |
Why?
|
| Social Class | 1 | 2023 | 310 | 0.210 |
Why?
|
| Hospital Mortality | 2 | 2020 | 1274 | 0.200 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 309 | 0.200 |
Why?
|
| Cholangiography | 1 | 2021 | 36 | 0.200 |
Why?
|
| Luminescent Proteins | 3 | 2010 | 289 | 0.200 |
Why?
|
| Surgical Oncology | 2 | 2020 | 190 | 0.200 |
Why?
|
| Deoxycytidine | 3 | 2018 | 1353 | 0.190 |
Why?
|
| Technology | 1 | 2021 | 96 | 0.190 |
Why?
|
| Coloring Agents | 1 | 2021 | 234 | 0.190 |
Why?
|
| Indocyanine Green | 1 | 2021 | 117 | 0.190 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 158 | 0.190 |
Why?
|
| Adult | 17 | 2021 | 77950 | 0.180 |
Why?
|
| Prognosis | 11 | 2023 | 21713 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 4892 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
| Propensity Score | 1 | 2023 | 750 | 0.180 |
Why?
|
| Animals | 16 | 2022 | 59536 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.170 |
Why?
|
| Tumor Burden | 4 | 2021 | 1987 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2021 | 6869 | 0.170 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 60 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 1225 | 0.170 |
Why?
|
| Neoplasm Transplantation | 3 | 2011 | 1519 | 0.170 |
Why?
|
| Device Removal | 2 | 2018 | 337 | 0.170 |
Why?
|
| Young Adult | 7 | 2021 | 21445 | 0.170 |
Why?
|
| Surgical Wound Infection | 2 | 2023 | 450 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2022 | 12873 | 0.160 |
Why?
|
| Streptozocin | 1 | 2018 | 75 | 0.160 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 25 | 0.160 |
Why?
|
| Trastuzumab | 1 | 2021 | 696 | 0.160 |
Why?
|
| Amylases | 1 | 2018 | 66 | 0.160 |
Why?
|
| Fascia | 1 | 2018 | 68 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 598 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2019 | 272 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 394 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2022 | 661 | 0.150 |
Why?
|
| Cisplatin | 2 | 2023 | 2432 | 0.150 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 117 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 4314 | 0.150 |
Why?
|
| Adolescent | 7 | 2021 | 31252 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 14889 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 941 | 0.140 |
Why?
|
| Nutritional Support | 1 | 2017 | 80 | 0.140 |
Why?
|
| Fluorouracil | 2 | 2018 | 1944 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 181 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 2 | 2020 | 634 | 0.140 |
Why?
|
| Pancreatic Fistula | 3 | 2022 | 99 | 0.140 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2016 | 145 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.130 |
Why?
|
| Patient Selection | 2 | 2020 | 2055 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2022 | 2803 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 130 | 0.130 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10001 | 0.130 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 92 | 0.130 |
Why?
|
| Quality of Life | 4 | 2019 | 4532 | 0.130 |
Why?
|
| Mice, Transgenic | 4 | 2013 | 4143 | 0.130 |
Why?
|
| Defecation | 1 | 2014 | 58 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 29902 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 348 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2022 | 1270 | 0.120 |
Why?
|
| Hospital Charges | 1 | 2014 | 75 | 0.120 |
Why?
|
| Comorbidity | 3 | 2019 | 2352 | 0.120 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 120 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1301 | 0.120 |
Why?
|
| Splenectomy | 1 | 2014 | 158 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 1226 | 0.110 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 2173 | 0.110 |
Why?
|
| Disease Progression | 4 | 2013 | 6682 | 0.110 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 610 | 0.110 |
Why?
|
| Survivors | 2 | 2016 | 1031 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2021 | 9180 | 0.110 |
Why?
|
| Incidence | 2 | 2023 | 5673 | 0.110 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 1946 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 5437 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 2083 | 0.100 |
Why?
|
| Pancreatitis | 1 | 2014 | 267 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2018 | 3005 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 479 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2518 | 0.100 |
Why?
|
| Databases, Factual | 4 | 2018 | 2218 | 0.090 |
Why?
|
| Xenon | 1 | 2010 | 19 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 30 | 0.090 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 116 | 0.090 |
Why?
|
| Integrin beta1 | 1 | 2011 | 126 | 0.090 |
Why?
|
| Lighting | 1 | 2010 | 27 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 297 | 0.090 |
Why?
|
| Subtraction Technique | 1 | 2010 | 141 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 716 | 0.090 |
Why?
|
| Operative Time | 2 | 2023 | 217 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 289 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2010 | 114 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4744 | 0.090 |
Why?
|
| Drug Prescriptions | 2 | 2022 | 289 | 0.090 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 55 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 475 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2010 | 267 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2009 | 185 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 275 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 223 | 0.080 |
Why?
|
| Rectum | 2 | 2023 | 467 | 0.080 |
Why?
|
| Ascites | 1 | 2009 | 198 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 12926 | 0.080 |
Why?
|
| Cell Line | 3 | 2010 | 5114 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1082 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 838 | 0.080 |
Why?
|
| General Surgery | 1 | 2011 | 326 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 399 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2010 | 1313 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2010 | 561 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 4971 | 0.070 |
Why?
|
| Inpatients | 2 | 2022 | 678 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 664 | 0.070 |
Why?
|
| Mutation | 6 | 2023 | 15179 | 0.070 |
Why?
|
| Pyrroles | 1 | 2010 | 576 | 0.070 |
Why?
|
| Lipids | 1 | 2010 | 644 | 0.070 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 324 | 0.070 |
Why?
|
| Risk Factors | 4 | 2023 | 17523 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4849 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 669 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 554 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2011 | 7226 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10035 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 10331 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2992 | 0.060 |
Why?
|
| Mastectomy, Segmental | 1 | 2010 | 1026 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.060 |
Why?
|
| Indoles | 1 | 2010 | 1009 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 5047 | 0.060 |
Why?
|
| Cell Survival | 1 | 2010 | 3045 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 1742 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2023 | 68 | 0.060 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 14 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 221 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 310 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 1756 | 0.050 |
Why?
|
| Age Factors | 1 | 2012 | 5377 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 1547 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 6942 | 0.050 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2022 | 71 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 240 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 70 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 273 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2022 | 149 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 1559 | 0.050 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 83 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 2170 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 245 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2021 | 122 | 0.050 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 42 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 138 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2023 | 611 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 285 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6311 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 82 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 275 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2019 | 127 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2018 | 12 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 38 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 42 | 0.040 |
Why?
|
| Cathartics | 1 | 2018 | 42 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11538 | 0.040 |
Why?
|
| Genes, ras | 1 | 2021 | 667 | 0.040 |
Why?
|
| Citric Acid | 1 | 2018 | 54 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 71 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 875 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 38 | 0.040 |
Why?
|
| Anal Canal | 1 | 2018 | 238 | 0.040 |
Why?
|
| Metronidazole | 1 | 2018 | 149 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 191 | 0.040 |
Why?
|
| Infant | 1 | 2012 | 13310 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 1090 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 1283 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 387 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2012 | 16273 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2084 | 0.030 |
Why?
|
| Pain | 1 | 2023 | 1658 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 2283 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 2809 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 2316 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 718 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 821 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2016 | 486 | 0.030 |
Why?
|
| Cell Movement | 2 | 2011 | 2466 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 690 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5395 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1165 | 0.020 |
Why?
|
| Child | 1 | 2012 | 29154 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 851 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2010 | 111 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2010 | 45 | 0.020 |
Why?
|
| Sarcoma | 1 | 2020 | 1725 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 315 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 548 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 11965 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 417 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 1008 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1077 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 1085 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1399 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8223 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1618 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 478 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 608 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1972 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 1555 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 1271 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 4917 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2010 | 1996 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 2450 | 0.010 |
Why?
|
| Proteomics | 1 | 2010 | 1380 | 0.010 |
Why?
|
| Melanoma | 1 | 2020 | 5317 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3639 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5687 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6009 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6150 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5159 | 0.010 |
Why?
|